RVNC Revance Therapeutics, Inc. Stock Quote

publish chart | save to portfolio | create alert

RVNC [NASD]

Revance Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-4.60	Insider Own	1.60%	Shs Outstand	60.53M	Perf Week	1.60%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-4.12	Insider Trans	-5.92%	Shs Float	58.15M	Perf Month	-4.80%
Income	-249.10M	PEG	-	EPS next Q	-1.22	Inst Own	80.50%	Short Float	7.14%	Perf Quarter	-14.75%
Sales	4.30M	P/S	379.34	EPS this Y	6.90%	Inst Trans	-2.23%	Short Ratio	6.67	Perf Half Y	14.24%
Book/sh	6.16	P/B	4.02	EPS next Y	12.90%	ROA	-44.90%	Target Price	35.80	Perf Year	38.96%
Cash/sh	6.62	P/C	3.74	EPS next 5Y	11.60%	ROE	-85.70%	52W Range	11.78 - 34.62	Perf YTD	52.74%
Dividend	-	P/FCF	-	EPS past 5Y	-2.50%	ROI	-72.90%	52W High	-28.39%	Beta	1.42
Dividend %	-	Quick Ratio	7.00	Sales past 5Y	1.50%	Gross Margin	74.20%	52W Low	110.44%	ATR	1.43
Employees	193	Current Ratio	7.10	Sales Q/Q	8237.00%	Oper. Margin	-	RSI (14)	46.52	Volatility	5.17% 5.60%
Optionable	Yes	Debt/Eq	0.48	EPS Q/Q	-40.40%	Profit Margin	-	Rel Volume	0.40	Prev Close	24.51
Shortable	Yes	LT Debt/Eq	0.48	Earnings	Nov 09 AMC	Payout	-	Avg Volume	622.41K	Price	24.79
Recom	1.80	SMA20	-3.93%	SMA50	-5.25%	SMA200	7.57%	Volume	246,939	Change	1.14%

Oct-15-20

Reiterated

Needham

Buy

$36 → $42

Aug-11-20

Resumed

Mizuho

Buy

$32

Mar-23-20

Downgrade

Goldman

Buy → Neutral

$32 → $15

Dec-02-19

Initiated

Goldman

Buy

Oct-30-19

Upgrade

Wells Fargo

Market Perform → Outperform

$20

Jun-11-19

Initiated

Barclays

Overweight

$28

Feb-15-19

Initiated

Wells Fargo

Market Perform

Feb-14-19

Initiated

H.C. Wainwright

Buy

$25

Jan-29-19

Initiated

Stifel

Buy

$50

Nov-16-18

Upgrade

Guggenheim

Neutral → Buy

Sep-17-18

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Apr-20-18

Reiterated

Mizuho

Buy

$54 → $48

Mar-27-18

Initiated

Needham

Buy

$42

Mar-05-18

Initiated

Goldman

Buy

$60

Jan-09-18

Downgrade

Guggenheim

Buy → Neutral

Dec-06-17

Reiterated

Mizuho

Buy

$37 → $54

Dec-06-17

Initiated

Guggenheim

Buy

$42

Nov-27-17

Initiated

Barclays

Overweight

$31

Nov-17-17

Initiated

Mizuho

Buy

$37

Aug-22-17

Initiated

JMP Securities

Mkt Outperform

$34

Nov-27-20 01:31PM	Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed Zacks
Nov-25-20 08:30AM	FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection Business Wire
Nov-24-20 04:05PM	Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-20-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-11-20 08:08AM	Analysts Have Made A Financial Statement On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Third-Quarter Report Simply Wall St.
Nov-10-20 04:05PM	Revance to Participate in the Stifel 2020 Virtual Healthcare Conference Business Wire -6.76%
08:40AM	The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga
Nov-09-20 05:16PM	Recap: Revance Therapeutics Q3 Earnings Benzinga
04:05PM	Revance Reports Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
04:05PM	Revance Announces Results of Phase 2 Trial of DaxibotulinumtoxinA for Injection in Plantar Fasciitis Business Wire
02:45PM	Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-20 09:00AM	Is a Surprise Coming for Revance (RVNC) This Earnings Season? Zacks
Nov-03-20 04:05PM	Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference Business Wire
Nov-02-20 04:05PM	Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020 Business Wire
Oct-23-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.82%
Oct-14-20 08:00AM	Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia Business Wire -7.68%
Oct-06-20 08:00AM	Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting Business Wire
Oct-05-20 10:15AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks
Sep-23-20 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-08-20 04:05PM	Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-02-20 08:00AM	Revance to Participate in the Wells Fargo Securities Healthcare Conference Business Wire
Aug-28-20 11:29AM	Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet? Simply Wall St.
Aug-25-20 08:00AM	Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers Business Wire
Aug-11-20 08:30AM	Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery Business Wire
Aug-06-20 04:05PM	Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update Business Wire
Jul-30-20 04:05PM	Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire
Jul-24-20 09:46AM	Revance Completes All-Stock Deal For HintMDs Payments Platform TipRanks
Jul-23-20 06:20PM	Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices Business Wire
Jul-05-20 03:28PM	Is Revance Therapeutics Inc (RVNC) Going to Burn These Hedge Funds? Insider Monkey
Jun-30-20 04:05PM	Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection Business Wire
08:00AM	Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crows Feet, Respectively Business Wire
Jun-26-20 09:57AM	Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher Zacks
Jun-18-20 12:27PM	Needham: 3 Conviction Buy Stocks to Snap up Now TipRanks
Jun-09-20 08:10PM	Edited Transcript of RVNC earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-04-20 04:05PM	Revance to Participate in the 40th Annual William Blair Growth Stock Conference Business Wire
Jun-02-20 04:05PM	Revance to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast Business Wire
03:31AM	Revance, Mylan Move Forward With Botox Rival; Analyst Sees Long Path Ahead SmarterAnalyst
Jun-01-20 08:30AM	Revance and Mylan to Advance Development Program for Biosimilar to BOTOX® Business Wire
May-20-20 08:12AM	Revance Acquires HintMD In All-Stock Deal, Analyst Praises Bold Step Forward SmarterAnalyst
May-19-20 08:01AM	Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices Business Wire
May-09-20 10:01PM	Revance Therapeutics (RVNC) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 04:05PM	Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update Business Wire
May-01-20 08:30AM	Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020 Business Wire -6.48%
Apr-30-20 04:05PM	Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 Business Wire
Apr-27-20 09:16AM	Revance's Shares March Higher, Can It Continue? Zacks +9.24%
Apr-21-20 08:05AM	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors GlobeNewswire
Apr-09-20 08:55AM	How Revance (RVNC) Stock Stands Out in a Strong Industry Zacks +8.05%
Apr-07-20 04:05PM	Revance to Participate in the 19th Annual Needham Virtual Healthcare Conference Business Wire
Mar-26-20 04:05PM	Revance Provides Corporate Update in Light of COVID-19 Business Wire
Mar-25-20 08:36AM	Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options Zacks +5.36%
Mar-07-20 12:26AM	Edited Transcript of RVNC earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-03-20 04:05PM	Revance to Participate in the Barclays Global Healthcare Conference 2020 Business Wire
Feb-27-20 01:08PM	Revance Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St. -7.22%
Feb-25-20 04:05PM	Revance to Participate in the Cowen 40th Annual Health Care Conference Business Wire -7.99%
Feb-24-20 04:05PM	Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update Business Wire
Feb-14-20 08:00AM	Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020 Business Wire
Feb-12-20 06:55AM	Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027 Business Wire
Feb-10-20 04:08PM	Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027 Business Wire
Feb-07-20 07:32AM	The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
Feb-06-20 08:00AM	Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines Business Wire
Jan-21-20 05:32AM	Will Revance Therapeutics Continue to Surge Higher? Zacks
Jan-19-20 09:13AM	3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside TipRanks
Jan-10-20 10:11AM	Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? Simply Wall St. +18.29%
08:05AM	Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA Business Wire
Jan-09-20 04:05PM	Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
08:05AM	Revance Provides Corporate Update and Anticipated Milestones for 2020 Business Wire
Dec-20-19 05:35PM	Did Hedge Funds Drop The Ball On Revance Therapeutics Inc (RVNC) ? Insider Monkey
Dec-05-19 08:00AM	Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology Business Wire
Dec-04-19 07:41AM	Revance Announces Pricing of Public Offering of Common Stock Business Wire -17.57%
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 04:01PM	Revance Announces Proposed Public Offering of Common Stock Business Wire
Dec-02-19 08:00AM	Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics Business Wire +11.87%
Nov-25-19 08:00AM	Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines Business Wire
Nov-24-19 04:19PM	The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More Benzinga
Nov-15-19 04:29PM	Edited Transcript of RVNC earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:05PM	Revance to Participate in the Stifel 2019 Healthcare Conference Business Wire
Nov-06-19 04:05PM	Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference Business Wire
Nov-05-19 06:43AM	3 Hot Biotech Stocks With 100% Street Support TipRanks
Nov-04-19 04:10PM	Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update Business Wire
04:05PM	Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia Business Wire
08:00AM	Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery Business Wire
Oct-30-19 01:09PM	Wells Fargo Turns Bullish On Revance Therapeutics After Meeting With Management Benzinga
09:46AM	Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy? Insider Monkey
Oct-28-19 04:05PM	Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019 Business Wire
Oct-23-19 08:00AM	Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting Business Wire
Oct-18-19 10:23AM	These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-15-19 05:04PM	Allergan (AGN) Shareholders Approve Acquisition by AbbVie Zacks
04:55PM	'Misjudgment' in employee matter leads to departure of East Bay drug maker CEO American City Business Journals
Oct-14-19 08:00AM	Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne Business Wire +15.11%
Oct-08-19 03:30PM	We're Hopeful That Revance Therapeutics (NASDAQ:RVNC) Will Use Its Cash Wisely Simply Wall St.
Oct-02-19 04:05PM	Revance Earns Great Place to Work® Certification for Second Year Business Wire
Sep-25-19 04:05PM	Revance to Participate in the 2019 Cantor Global Healthcare Conference Business Wire
Sep-04-19 04:05PM	Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-28-19 04:05PM	Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference Business Wire
Aug-23-19 12:06PM	Does Revance Therapeutics, Inc.'s (NASDAQ:RVNC) CEO Pay Compare Well With Peers? Simply Wall St.
Aug-12-19 09:10PM	Edited Transcript of RVNC earnings conference call or presentation 5-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 08:24PM	Revance Therapeutics (RVNC) Q2 2019 Earnings Call Transcript Motley Fool
Aug-05-19 04:05PM	Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update Business Wire
02:30PM	Revance Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-29-19 04:05PM	Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 Business Wire

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rankin Aubrey	President, Innovation & Tech	Oct 29	Sale	26.15	33,119	865,949	543,803	Oct 30 08:24 PM
Rankin Aubrey	President, Innovation & Tech	Sep 28	Sale	26.18	33,119	867,055	576,922	Sep 30 09:21 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience